검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 5개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Blenrep (belantamab mafodotin) | Belantamab mafodotin | Cytoxan | Adriamycin | Sirolimus |
Overview Company | GSK | GSK | Merck Sharp & Dohme LLC | Palleos Healthcare GmbH | Christopher Strouse |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | BCMA | Multiple Myeloma | Metastatic Breast Cancer | Hodgkin Lymphoma | FRα |
Overview Indication | Multiple myeloma | Multiple Myeloma | Multiple Myeloma, Refractory | Multiple Myeloma | Multiple Myeloma |
Overview Phase | APPROVED | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 |
Overview Status | DISCONTINUED | RECRUITING | RECRUITING | ACTIVE | DISCONTINUED |
MoA Mechanism | BCMA binding → MMAF payload delivery | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | targeted metabolomics analysis based on UPLC-MS/MS and a reverse transcription polymerase chain reaction (RT-qPCR) technology were used to explore the specific metabolic pathway | target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway | target synergy, effectively inhibits the PI3K pathway |
MoA Biomarker | BCMA expression | biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and | EGFR gene exhibited the high | biomarkers in serum, besides histopathological alterations in rats' liver and kidney | — |
PK/PD Half-life | 16.8 h | 16.8 h | — | 78.4 days | — |
PK/PD Species | Cynomolgus monkey | Cynomolgus monkey, Human | Mouse | Mouse | Mouse, Human |
PK/PD Animal (cat.) | NHP | Human, NHP | Mouse | Mouse, In vitro | Human, Mouse, In vitro |
PK/PD Experiment | Pd | Pharmacokinetic | PK | pharmacokinetic | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse, Rat, Human | Mouse | Mouse | Mouse, Rat, Hamster, Human |
Toxicology Animal (cat.) | Mouse, Rat | Mouse, Rat | Mouse | Mouse, In vitro | Mouse, Rat |
Toxicology Major finding | hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract, and COVID-19 | hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract, and COVID-19 | A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment of patients with nonmalignant or malignant blood disorders. Its success has been limited by graft-versus-host disease (GVHD). Current systemic nontargeted conditioning regi… | thrombocytopenia who was diagnosed with DC based on clinical features and genetic testing | Hepatotoxicity, including fatal hepatic necrosis, with elevated sirolimus trough concentrat |
Toxicology CRS | — | — | grade 4 | — | — |
Clinical Primary efficacy | ORR 31% | ORR 100% | ORR 95% | ORR 95% | ORR 9% |
Clinical ORR | 31% (DREAMM-2) | 100% | 95.0% | 95.0% | 9% |
Clinical PFS | 2.9 mo | — | — | — | — |
Clinical Result source | DREAMM-2 | ClinicalTrials.gov NCT03828292 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT02357342 |
Clinical Data Tier / Score | A · 64 | S · 69 | B · 62 | C · 59 | C · 16 |
Clinical Program phase | APPROVED | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (9일 전) | 2026년 7월 6일 (21일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) | 2026년 7월 8일 (19일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 5개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Blenrep (belantamab mafodotin) | Belantamab mafodotin | Cytoxan | Adriamycin | Sirolimus |
Overview Company | GSK | GSK | Merck Sharp & Dohme LLC | Palleos Healthcare GmbH | Christopher Strouse |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | BCMA | Multiple Myeloma | Metastatic Breast Cancer | Hodgkin Lymphoma | FRα |
Overview Indication | Multiple myeloma | Multiple Myeloma | Multiple Myeloma, Refractory | Multiple Myeloma | Multiple Myeloma |
Overview Phase | APPROVED | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 |
Overview Status | DISCONTINUED | RECRUITING | RECRUITING | ACTIVE | DISCONTINUED |
MoA Mechanism | BCMA binding → MMAF payload delivery | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | targeted metabolomics analysis based on UPLC-MS/MS and a reverse transcription polymerase chain reaction (RT-qPCR) technology were used to explore the specific metabolic pathway | target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway | target synergy, effectively inhibits the PI3K pathway |
MoA Biomarker | BCMA expression | biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and | EGFR gene exhibited the high | biomarkers in serum, besides histopathological alterations in rats' liver and kidney | — |
PK/PD Half-life | 16.8 h | 16.8 h | — | 78.4 days | — |
PK/PD Species | Cynomolgus monkey | Cynomolgus monkey, Human | Mouse | Mouse | Mouse, Human |
PK/PD Animal (cat.) | NHP | Human, NHP | Mouse | Mouse, In vitro | Human, Mouse, In vitro |
PK/PD Experiment | Pd | Pharmacokinetic | PK | pharmacokinetic | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse, Rat, Human | Mouse | Mouse | Mouse, Rat, Hamster, Human |
Toxicology Animal (cat.) | Mouse, Rat | Mouse, Rat | Mouse | Mouse, In vitro | Mouse, Rat |
Toxicology Major finding | hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract, and COVID-19 | hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract, and COVID-19 | A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment of patients with nonmalignant or malignant blood disorders. Its success has been limited by graft-versus-host disease (GVHD). Current systemic nontargeted conditioning regi… | thrombocytopenia who was diagnosed with DC based on clinical features and genetic testing | Hepatotoxicity, including fatal hepatic necrosis, with elevated sirolimus trough concentrat |
Toxicology CRS | — | — | grade 4 | — | — |
Clinical Primary efficacy | ORR 31% | ORR 100% | ORR 95% | ORR 95% | ORR 9% |
Clinical ORR | 31% (DREAMM-2) | 100% | 95.0% | 95.0% | 9% |
Clinical PFS | 2.9 mo | — | — | — | — |
Clinical Result source | DREAMM-2 | ClinicalTrials.gov NCT03828292 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT02357342 |
Clinical Data Tier / Score | A · 64 | S · 69 | B · 62 | C · 59 | C · 16 |
Clinical Program phase | APPROVED | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (9일 전) | 2026년 7월 6일 (21일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) | 2026년 7월 8일 (19일 전 · 갱신 권장) |
추천 비교
추천 비교